



(Stock Code: 00690.HK)

Uni-Bio Science Group opens Hong Kong research centre

Future R&D focus in four major businesses

[13 June 2022 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”; Stock code: 00690.HK) is pleased to announce the launch of its new research centre in Hong Kong, focused in conducting research on stem cell exosomes, synthetic biology, nanomaterials, and protein engineering. By leveraging the mature scientific ecosystem of the Hong Kong Science Park, the new laboratory can quickly and efficiently develop new innovative bio-products, enabling the expansion of the Group's product line, reshaping the R&D system, and opening up new room for strategic growth.

The four major business "combination punch"

The official operation of the new Hong Kong R&D platform marks the official upgrade of the Group's business model to a "four-wheel drive" model, which includes high-value generic drugs, bio-innovative drugs, new skincare raw materials and CMO, especially focusing in diabetes, ophthalmology, orthopedics and other therapeutic areas. The new R&D model provides the Group with a diversified asset base, as well as generate new growth “S-curves” opportunities in the near future.

First of all, high-value generic drugs are one of the important "ammunitions" for pharmaceutical companies in the context of reducing the burden of medical insurance. The Group's product, BOSHUTAI® (Acarbose Tablets), was successfully selected for centralized procurement by the Henan Thirteen Provinces Alliance at a reasonable price on 2nd June this

year. As early as last year, the Group's antifungal drug PINUP® (Voriconazole Tablets) also stood out from the competition, taking the first place in procurement volume. In the future, these two products will continue to gain market share and contribute to a stable source of cashflow. It is worth mentioning that the Group has recently kicked off development of single-use diquafosol eye drops (no preservatives), indicated for dry eye syndrome, through strategic cooperation with API manufacturers. The proposed single-use form utilizes cutting-edge BFS manufacturing technology deployed by the Group, is safer and more convenient to use when compared to traditional multi-dose droppers.

Secondly, innovative biological drugs are the "source" of the company's vitality. The Group's blockbuster product under development, Uni-PTH, is expected to submit a new drug marketing application this year. The clinical work of Uni-GLP-1 injection pen is also being accelerated, and the development of oral dosage forms is also under preparation. In addition, the sales of the Group's core products GeneTime® and GeneSoft® had fully recovered strongly since the pandemic. The resilience of the product in such challenging period represents the products competitive edge in the market. Hence, the Group is doubling down on the product by explore innovative formulation of EGF, such as BFS dosage and nanofiber forms, to further extend the product life cycle, expand the scope of application, and continue to release value. As for the most cutting-edge innovation, the Group is also exploring new drug candidates using new antibody modalities, such as the partnership to develop single domain antibodies for the use of AMD and other retinal diseases.

In terms of new skincare raw materials, the Group is leading product innovation with material innovation. Especially when efficacy skin care is increasingly popular, synthetic biology is becoming a key research direction with disruptive potential in the cosmeceutical space. The new skincare raw materials under research in the new laboratory of the Group include: collagen, fibronectin, beauty peptides, probiotics, and exosomes. The materials are safe in composition, excellent in efficacy and widely used. The Group will effectively leverage the research ecosystem of HKSTP, as well as Uni-Bio's bioprocessing platform to quickly commercialize these 5 products. The earliest products can hit the market as early as 1H2023.

Finally, the Group's CMO business leverages on the existing strong know-how of commercialization and bio-manufacturing, the Group has previously launched a three-in-one pre-filled syringe/lyophilized powder manufacturing line, which can meet the pilot and clinical sample processing of vial injection/lyophilized powder, cartridge injection and pre-filled injection, and it has attracted strategic cooperation with multiple customers over the past few years. Seeing the success of the CMO business, the Group plans to invest further to expand its

CMO capacity to cover a wider range of potential clients, as well as integrate new manufacturing technologies to provide a differentiated solution compared to other market participants.

Innovation empowerment, hard work, and strategic blueprint

As an excellent enterprise integrating R&D, production and sales in the field of biological peptides, the Group attaches great importance to R&D innovation and builds a "small but beautiful" R&D platform, tightly integrating production, education and research. The dedication to innovation can be proven in 2021 where the Group's R&D expenses increased by 23.3% year-on-year to HK\$50.2 million, even amid the raging COVID-19 pandemic. Even this year, the Group is actively expanding research and development cooperation channels, carry out multi-level research and development cooperation with the Chinese University of Hong Kong, NAMI, etc., and sharing technological achievements to further enhance the company's comprehensive research and development strength.

However, the success in the field of biomedicine or creating a strong enterprise are not achieved overnight, and there is no "easy solution". It requires long-term investment, repeated experiments, and continuous research and development. "Innovation is the driving force behind the development of pharmaceutical companies. To this end, we must dig deep into innovation and broaden the path of innovation. In the past five years, an average of 20% of our revenue has been invested in innovation and research and development, because it is difficult to make good products without accumulation of knowhow and data. What we want to do is to benefit more patients and improve the quality and value of medicines." said Dr. Li, head of group research and development.

In the future, the Group will adhere to the "Strong R&D" route, continuously cultivate its internal strength. In the short term, the existing product lines will continue to contribute stable revenue to the Group. In the mid-term, the continuous iteration of epidermal growth factor products to expand dosage forms and application scenarios will foster a strong EGF franchise and core branding for the Group. In the long run, we are committed to cutting-edge products in the medical and aesthetic, diabetes and other endocrine space. The Group is particularly excited at the prospects of its oral GLP-1, and injection-free single domain antibody programs.

-End-

About Uni-Bio Science Group

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of biopharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine as diabetes and osteoporosis, ophthalmology and dermatology. Please visit the official website of Uni-Bio Science Group for more information: www.uni-bioscience.com/

For further information, please contact:

E-mail: ir@uni-bioscience.com